(Total Views: 337)
Posted On: 06/22/2020 10:19:40 AM
Post# of 36567
Item 8.01 Other Events.
On April 17, 2020, Generex Biotechnology Corporation (“Generex”) received a letter of support from WCCT Global, Inc. (WCCT), regarding Generex’s efforts to develop Generex’s li-Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. A copy of the letter of support is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
About WCCT Global, Inc.
WCCT is a multisite, full-service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase CRO services to the pharmaceutical, biotechnology and medical device industries. They are the specialized global drug development professionals who offer an innovative, agile and collaborative approach to every program it delivers. WCCT’s Mission: To advance global health by transforming clinical research.
Forw
On April 17, 2020, Generex Biotechnology Corporation (“Generex”) received a letter of support from WCCT Global, Inc. (WCCT), regarding Generex’s efforts to develop Generex’s li-Key-SARS-CoV-2 peptide vaccine with the goal to begin mass vaccination in the Fall of 2020. A copy of the letter of support is attached to this report as Exhibit 99.1 and is incorporated by reference herein.
About WCCT Global, Inc.
WCCT is a multisite, full-service pharmaceutical contract research organization (CRO) of outsourced early drug development and late phase CRO services to the pharmaceutical, biotechnology and medical device industries. They are the specialized global drug development professionals who offer an innovative, agile and collaborative approach to every program it delivers. WCCT’s Mission: To advance global health by transforming clinical research.
Forw
(0)
(0)
